In sub-Saharan Africa, antivenoms for snake bites pose significant challenges due to poor regulation and efficacy. Patients like Kamidikolo Badilu suffer severe consequences from ineffective treatments, with cases showing that over 70 vials may be necessary for proper care. Research reveals that many antivenoms are unreliable, some produced under fraudulent circumstances, and often not put through necessary clinical trials. This lack of quality assurance has led to dire situations for snakebite victims, as expressed by Thea Litscha-Koen, highlighting the urgent need for better regulation and access to reliable medical treatments.
Thea Litscha-Koen expressed grave concerns, stating, "It's a cowboy show out there. Some of them are selling stuff that, honestly, you may as well just pour down the drain."
The Bureau of Investigative Journalism found that over 70 vials of certain antivenoms are required for effective treatment, indicating severe issues with their efficacy.
Collection
[
|
...
]